Thymidylate Synthase (TYMS) (NM_001071) Human Recombinant Protein

CAT#: TP710029

Recombinant protein of human thymidylate synthetase (TYMS), full length, with N-terminal polyhistidine tag, expressed in sf9 cells.

Product Images

Specifications

Product Data

• Species: Human
• Expression Host: Sf9
• Expression cDNA Clone or AA Sequence:
  Protein Sequence

  A DNA sequence from TrueORF clone, RC204814, encoding human full-length TYMS
• Tag: N-His
• Predicted MW: 36 kDa
• Concentration: >50 ug/mL as determined by microplate BCA method
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining
• Buffer: 50mM Tris-HCl pH8.0, 150mM NaCl, 10% glycerol
• Storage: Store at -80°C.
• Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.

Reference Data

• RefSeq: NP_001062
• Locus ID: 7298
• UniProt ID: P04818, Q53Y97
• Cytogenetics: 18p11.32
• Refseq Size: 1536
• Refseq ORF: 939
• Synonyms: HST422; TMS; TS
• Summary: 'Thymidylate synthase catalyzes the methylation of deoxyuridylate to deoxythymidylate using, 10-methylenetetrahydrofolate (methylene-THF) as a cofactor. This function maintains the dTMP (thymidine-5-prime monophosphate) pool critical for DNA replication and repair. The enzyme has been of interest as a target for cancer chemotherapeutic agents. It is considered to be the primary site of action for 5-fluorouracil, 5-fluoro-2-prime-deoxyuridine, and some folate analogs. Expression of this gene and that of a naturally occurring antisense transcript, mitochondrial enolase superfamily member 1 (GeneID:55556), vary inversely when cell-growth progresses from late-log to plateau phase. Polymorphisms in this gene may be associated with etiology of neoplasia, including breast cancer, and response to chemotherapy. [provided by RefSeq, Aug 2017]'
• Protein Families: Druggable Genome
• Protein Pathways: Metabolic pathways, One carbon pool by folate, Pyrimidine metabolism